Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Globus Medical

GMEDNYSEHealth Care EquipmentWILMINGTON, US-DE, USMid capWebsite ↗
  • Russell 1000
  • MidCap 400

What Globus Medical is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $3.14 billion, up 19% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.76 billion, up 43% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.15 billion, up 7.1% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $0.30 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 6, 2026): sentiment 0.60 on a −1 to +1 scale (mixed), confidence 0.80 of 1.Palanor Discourse
  • Guidance in the last 90 days: 1 outlook figure raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 24, 2026): 1 risk factor added, 5 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q3 2026: $4.4 million on the open market.SEC Form 4
  • 598 institutional managers reported a position at June 30, 2026 (−9 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 19 (13 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

Company Posture covers S&P 500 companies.

Credit

How these are built →

No bond term sheets or tagged debt on file for Globus Medical yet.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Globus Medical: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$0.76BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Globus Medical: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Globus Medical: revenue, trailing twelve months

$ billions, from SEC filings

$3.1BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Globus Medical: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.30BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Globus Medical: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

1,158Data to Jun 2020
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Globus Medical: guidance raised minus lowered

Guidance Ledger statements by quarter

1.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Globus Medical: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.60Data to Aug 2026
ImageDataPalanor calculation
Business

Globus Medical: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Globus Medical: risk factors added per annual report

New Item 1A risk factors in each 10-K

1.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Globus Medical: H-1B filings certified

Labor Condition Applications by quarter received

19.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Globus Medical: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$4.4MData 23 days ago
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Globus Medical: institutional holders

Managers reporting a position on Form 13F, by quarter

598.0Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 21, 2026Lobbying
    Lobbying report (BALLARD SPAHR LLP)third_quarter 2026
  2. Oct 20, 2026Lobbying
    Lobbying report (BALLARD SPAHR LLP)third_quarter 2026
  3. Oct 20, 2026Patent
    Patent granted: SMART SURGICAL INSTRUMENTSUS 12765956
  4. Oct 20, 2026Patent
    Patent granted: EXPANDABLE TIBIAL TRAY INSERT TRIALUS 12766012
  5. Oct 20, 2026Patent
    Patent granted: EXPANDABLE FUSION IMPLANT AND RELATED METHODSUS 12766007
  6. Oct 20, 2026Patent
    Patent granted: LATERALLY INSERTABLE INTERVERTEBRAL SPINAL IMPLANTUS 12766010
  7. Oct 15, 2026Trademark
    Trademark application: TENCIL
  8. Oct 13, 2026Patent
    Patent granted: SYSTEMS AND METHODS FOR FIXATING A NAVIGATION ARRAYUS 12758237
  9. Aug 27, 2026Trademark
    Trademark application: HFX ELITE
  10. Jul 20, 2026Lobbying
    Lobbying report (BALLARD SPAHR LLP)second_quarter 2026
  11. Jun 19, 2026Trademark
    Trademark application: HFX ADAPTIVEAI
  12. Jun 4, 20268-K
    Director or officer changeItem 5.02
  13. Jun 4, 20268-K
    Shareholder vote resultsItem 5.07
  14. May 11, 2026Trademark
    Trademark application: H2
  15. Apr 20, 2026Lobbying
    Lobbying report (BALLARD SPAHR LLP)first_quarter 2026
  16. Mar 31, 2026Trademark
    Trademark application: REDEEM
  17. Mar 23, 20268-K
    Director or officer changeItem 5.02
  18. Feb 24, 202610-K
    Annual report (10-K)1 risk factors added, 5 removed
  19. Jan 20, 2026Lobbying
    Lobbying report (BALLARD SPAHR LLP)fourth_quarter 2025
  20. Oct 20, 2025Lobbying
    Lobbying report (BALLARD SPAHR LLP)third_quarter 2025
  21. Jul 21, 20258-K
    Director or officer changeItem 5.02
  22. Jul 21, 2025Lobbying
    Lobbying report (BALLARD SPAHR LLP)second_quarter 2025
  23. Jun 5, 20258-K
    Director or officer changeItem 5.02
  24. Jun 5, 20258-K
    Shareholder vote resultsItem 5.07
  25. May 13, 2025Risk event
    OSHA complaint inspection: GLOBUS MEDICAL, INC.OSHA
  26. Apr 21, 2025Lobbying
    Lobbying report (BALLARD SPAHR LLP)first_quarter 2025
  27. Apr 3, 20258-K
    Acquisition or sale completedItem 2.01
  28. Mar 10, 2025Risk event
    OSHA referral inspection: GLOBUS MEDICAL INC.OSHA
  29. Feb 20, 202510-K
    Annual report (10-K)2 risk factors added, 0 removed
  30. Feb 6, 20258-K
    Material agreement signedItem 1.01
  31. Feb 21, 202410-K
    Annual report (10-K)6 risk factors added, 0 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Insulet Corporation PODD$3.0B$0.3BJun 30, 2026
Revvity RVTY$2.9B$0.6BJul 5, 2026
Bruker BRKR$3.5B$0.1BJun 30, 2026
Teleflex TFX$2.3B$0.2BJun 30, 2026
Idexx Laboratories IDXX$4.5B$1.3BJun 30, 2026
Dexcom DXCM$5.0B$1.4BJun 30, 2026
ResMed| RMD$5.7B$1.6BJun 30, 2026
Steris STE$6.0B$0.9BJun 30, 2026

Identity

SEC CIK
1237831
LEI
5299003M2P4CIK0RF205
Wikidata
Q18344949

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.